gad | CARLAT PUBLISHING

Clinical Update

Special Report: Refractory Anxiety Disorders Part 2: When First Lines Fail

March 1, 2024

Sarah K. Rivelli, MD, FACP, FAPA. System Director, Consult Liaison, Department of Psychiatry and Behavioral Medicine, Carilion Clinic. Chris Aiken, MD. Editor-in-Chief, The Carlat Psychiatry Report; Assistant Professor, NYU Langone Department of Psychiatry; practicing psychiatrist, Winston-Salem, NC.

The authors have no financial relationships with companies related to this material.

In Part 2 of our special report, we explain how you can treat various types of treatment-resistant anxiety—specifically, generalized anxiety disorder, panic disorder, and social anxiety disorder.

Buspirone: Still Effective After All These Years?

February 3, 2021

Eugene Rubin, MD.

Eugene Rubin, MD. Psychiatrist in private practice, Bingham Farms, MI. Dr. Rubin has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Buspirone (Buspar) is approved for generalized anxiety disorder, but its efficacy there is often questioned. Here we find out how it stacks up against the benzos and SSRIs, and explore its off-label potential in depression, sexual dysfunction, alcoholism, traumatic brain injury, and premenstrual dysphoric disorder.

Silexan: A Novel Anxiolytic

July 30, 2020

Chris Aiken, MD.

Chris Aiken, MD. Editor-in-Chief of TCPR. Practicing psychiatrist, Winston-Salem, NC. Dr. Aiken has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

This German medication outperformed paroxetine in generalized anxiety disorder and is available over the counter in the U.S.